Previous 10 | Next 10 |
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
Agilent (NYSE: A ) initiated with Overweight rating and $100 (18% upside) price target at Wells Fargo. More news on: Agilent Technologies, Inc., Avantor, Inc., Axonics Modulation Technologies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
PALO ALTO, Calif. , Jan. 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present a company overview at the J.P...
The top 10 stocks of 2019 are an interesting group. You might think tech stocks would dominate the upper echelon of equities, but you'd be wrong. As we saw in the IPO market , individual healthcare stocks actually had the strongest returns last year. Seven biotech companies made our list, inc...
Success is a science; if you have the conditions, you get the result. - Oscar Wilde To say that Kodiak Sciences (NASDAQ: KOD ), a US-based biopharmaceutical company, has enjoyed a great year would be an understatement. Shares of the company opened this year trading at $7.06 a share befo...
Kodiak Sciences (NASDAQ: KOD ) initiated with Buy rating and $100 (47% upside) price target at Jefferies. Shares up 1% premarket. More news on: Kodiak Sciences Inc., Tivity Health, Inc., Endo International plc, Healthcare stocks news, Stocks on the move, , Read more ...
2019 will go down in history as one of the best years ever for the stock market. Biotech stocks , in general, have performed very well. And some biotech stocks have delivered staggering gains. Axsome Therapeutics (NASDAQ: AXSM) , Constellation Pharmaceuticals (NASDAQ: CNST) , and Kodiak...
This has been a great year for the overall stock market and a banner year for a handful of drugmakers that don't even have a product to sell yet. These three biotech stocks entered 2019 ready to provide market-thumping returns, and they delivered. Let's look at what made them the industry...
Kodiak Sciences ( KOD ) is a biotech that should be closely watched by investors. It had enacted an agreement with Baker Bros. Advisors to sell its future royalties for a particular drug. The drug included as part of the deal is known as KSI-301 for the treatment of retinal vascular disord...
Biotech, hands down, wins the race for out-performance in the healthcare sector. Delivering new, valuable medicines has proven to be a winning strategy, even if the growth in their stocks is based on the hope of future drugs. However, this list focuses on the top 10 healthcare stocks in 2019, n...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...